SRC and non-small cell lung carcinoma: Src has been reported to elicit cigarette smoking extract (CSE)-induced EMT and resistance to gefitinib, while N-acetylcysteine (NAC) abrogates the resistance through alleviating Src activation and EMT, providing a clue that simultaneous targeting of EGFR-TKI and Src may help in clinical outcomes in EGFR-mutated NSCLC patients with smoking history (37).